Intellia Therapeutics, a genome editing company based in Cambridge, Massachusetts, has named Caroline Dorsa to its Board of Directors. Her appointment will help advance the company’s mission of developing therapeutics utilizing CRISPR/Cas9 gene-editing technology.Watch Full Movie Online Streaming Online and Download
“We are excited to have Caroline join our Board of Directors at such an important stage in Intellia’s growth and during the rapid acceleration of the gene-editing industry,” stated Nessan Bermingham, Founder and CEO at Intellia. “We are fortunate to benefit from her extensive board and business experience, particularly in finance, corporate governance, risk management and compensation, as we grow a sustainable company with transformational treatments for patients,” he added.
With over 30 years of diverse experience and management in the public sector and regulated industries, Dorsa also serves on the board for Biogen, where she chairs the audit committee, a responsibility she also holds at Joule Unlimited, a privately held bioenergy company.
Dorsa recently retired from her role as Executive Vice President and CFO of Public Service Enterprise Group, an integrated provider of regulated utility electric and gas distribution services. Prior to that she served as Senior Vice President, Global Human Health, Strategy and Integration for Merck & Co. and Senior Vice President and CFO at Avaya, where she oversaw its leveraged buyout in 2007.
Intellia’s investors include Atlas Venture, OrbiMed Healthcare Fund Management and Novartis, as well a number of public and private sector funds. The firm’s board of directors is comprised of Bermingham, Jean-François Formela, Carl L. Gordon, Rachel Haurwitz, John Leonard and Dorsa.